The VISKA Approach
At VISKA.BIO, we propose a unique way to target cancer through the body's innate immune system. Our innovative fusion protein will act to kill circulating cancer cells and prevent recurrence of cancer.
Our Therapeutic Candidate: An Antibody Complex Linked to Xanthine Oxidase
We have accomplished construction of a fusion protein which binds tightly to target EGFR and has substantial xanthine oxidase (XO) activity.
The fusion protein kills tumor cells expressing EGFR and elicits immunogenic cell death markers from dying cells, including surface calreticulin, HMGB1, and extracellular ATP.
Targeting “Cold” Tumors
Current immune-checkpoint inhibitors are only effective against 15-20% of cancers. At VISKA, our aim is to help patients who have cancers resistant to traditional immunotherapy treatments. These cancers, termed “cold,” can be made sensitive to our fusion protein through activation of specific cellular machinery.